1. Hong Kong Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: other
PuraPharm Corp. Ltd.

PuraPharm Corp. Ltd.

HHKEX:1498
0.24
HKD
+0.00
(-1.24%)
189.94MMarket Cap
Mar 31Next Earn
PuraPharm Corp. Ltd.
HKEX:1498
(Hong Kong Exchange)

Recent

price

0.24

P/E

ratio

- -

div

yld

- -

ROIC.AI

2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
HKD
1.54
2.29
2.27
2.35
2.76
2.67
1.62
1.68
1.14
1.03
0.97
0.8
- -
Revenue per Share
0.14
0.14
0.14
0.01
0.08
-0.87
0.09
-0.31
-0.3
-0.27
-0.09
-0.08
- -
Basic EPS, GAAP
0.08
-0.22
-0.49
-0.66
0.09
0.13
0.1
-0.05
0.16
0.15
0.22
0.06
- -
Free Cash Flow per Basic Share
- -
- -
0.08
0.02
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
0.57
1.97
1.91
2.09
2.14
1.3
1.3
1.02
0.65
0.39
0.28
0.24
0.24
Book Value per Share
0.54
1.93
1.8
1.18
1.24
0.86
0.96
0.86
0.5
0.25
0.16
0.09
0.09
Tangible Book Value per Share
238
207
237
252
270
261
371
394
395
395
395
419
430
Basic Weighted Avg Shares
366
474
536
592
746
696
602
660
448
407
382
336
- -
Sales/Revenue/Turnover
15.23
10.94
8.99
0.99
3.3
-6.29
11.92
6.52
-9.88
-9.12
-4.41
-6.66
- -
Operating Margin (%)
14
13
17
27
37
67
48
50
49
49
55
45
- -
Depreciation Expense
34
28
32
2
21
-227
32
-122
-120
-106
-35
-35
- -
Net Income, GAAP
18.48
29.09
16.82
81.72
21.58
- -
21.15
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
9.41
6.01
6
0.32
2.79
-32.66
5.27
-18.48
-26.83
-26.07
-9.28
-10.48
- -
Profit Margin (%)
23
315
256
8
131
-41
16
-54
-179
-222
-223
-252
-252
Working Capital
- -
- -
- -
54
164
186
213
111
75
103
100
67
67
LT Debt
136
470
455
549
562
362
512
402
258
153
111
130
130
Total Equity
- -
8.21
6.34
0.17
1.91
- -
5
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
7.82
6.09
0.55
3.44
- -
5.45
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
9.4
6.96
0.38
3.74
-49.17
7.26
-26.69
-36.44
-51.56
-26.8
-29.15
- -
Return on Common Equity (%)

Capital Structure

HKD

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
ST Debt
264
261
284
LT Borrowings
89
97
56
LT Finance Leases
10
16
12
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
395
395
535
Market Capitalization
217
194
190

Working Capital

HKD

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
Total Current Assets
268
232
227
Cash, Cash Equivalents & STI
13
17
16
Accounts Receivable, Net
103
88
95
Inventories
124
83
99
Total Current Liabilities
491
448
479
Payables & Accruals
- -
- -
- -
ST Debt
264
261
284
Deferred Revenue
- -
- -
- -

Growth Rates

HKD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-8.23%
-21.59%
17.34%
Free Cash Flow
-46.44%
-119.07%
-70.67%
Net Income, GAAP
-95.06%
-112.93%
-0.61%
Sales/Revenue/Turnover
-2.05%
-9.96%
-12.03%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

HKD

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
407
2024
- -
- -
382
2025
- -
- -
336

Semi-annual Earnings Per Share

HKD

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
-0.27
2024
- -
- -
-0.09
2025
- -
- -
-0.08

Semi-annual Dividends Per Share

HKD

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
- -
2024
- -
- -
- -
2025
- -
- -
- -
Similar Companies
Cipla Ltd (NSE:CIPLA)
Aurobindo Pharma Ltd (NSE:AUROPHARMA)
Lupin Limited (NSE:LUPIN)
Granules India Limited (NSE:GRANULES)
Revolution Medicines, Inc. (NASDAQ:RVMD)
Egyptian International Pharmaceutical Industries Co. (EGX:PHAR)
Business
PuraPharm Corporation Limited (1498.HK), an investment holding company founded in 1998 and headquartered in Tai Po, Hong Kong, engages in the research, development, production, marketing, and sale of concentrated Chinese medicine granules (CCMG) under the Nong's brand and Chinese healthcare products; it operates through segments including China CCMG, Hong Kong CCMG, Chinese healthcare products, clinics, and plantation, with manufacturing facilities in Nanning, Guangxi, China, that comply with PRC GMP, Australian TGA, and CNAS ISO 17025 standards. The company offers over 600 CCMG products for professional use by Chinese medical practitioners, hospitals, and clinics, alongside over-the-counter health products under brands such as PuraGold, Oncozac, Haveron, and Immuzac; it provides Chinese medicine clinic management systems, operates Nong’s clinics offering diagnostic services and CCMG products, engages in raw Chinese herb plantation and trading, and sells traditional Chinese medicine decoction pieces through online platforms and healthcare institutions in Hong Kong, Mainland China, and internationally. PuraPharm holds the leading 70% market share in Hong Kong CCMG by prescription revenue and is the only non-PRC firm licensed by China NMPA to manufacture CCMG in China, with products recognized by the United States Pharmacopeia. Recent developments include the announcement in October 2025 of a discloseable and connected transaction involving a patent licence agreement with issuance of consideration shares under specific mandate and subscription of new shares; an interim report released in September 2025; appointment of a new independent non-executive director in August 2025; interim results for the six months ended 30 June 2025 announced in August; and a profit warning alongside the patent licence and share subscription proposals in July 2025, alongside ongoing capital reduction efforts and board changes earlier in 2025.